

elf atochem

See Original



ELF ATOCHEM NORTH AMERICA, INC.
900 First Avenue, P.O. Box 1536
King of Prussia, PA 19406-0018

Tel. 215-397-6500

(A)

8EHQ-059A-13117

419-589... & ENVIRONMENTAL SERVICES
FILE: *TSCA/8(e)/n-propylethanolamine*

March 1, 1994

**FEDERAL EXPRESS
RETURN RECEIPT REQUESTED**

Document Processing Center (TS-790)
Office of Toxic Substances
Environmental Protection Agency
401 M St. S.W.
Washington, D.C. 20460
Attn: Section 8(e) Coordinator

Subject: TSCA Section 8(e) Submission

Contains No CBI



RECEIVED
OPPT/ODIC
94 MAY 20 AM 9:56



Dear Sir/Madam:

Elf Atochem North America Inc. has received preliminary results of an acute dermal toxicity study in rats and is submitting the results of this study to the Environmental Protection Agency (EPA) pursuant to Toxic Substances Control Act (TSCA) Section 8(e). This study does not involve effects in humans. The study provides information on n-Propylethanolamine (CAS No. 16369-21-4) and does not involve effects in humans.

Nothing in this letter or the enclosed study report is considered confidential business information of Elf Atochem.

The following is a summary of the adverse effects observed in the acute dermal toxicity study:

n-Propylethanolamine was administered to three groups of ten rats at a single intact skin site for a 24-hour exposure period at dose levels of 1000, 2000 and 3200 mg/kg. Three of ten animals died at 1000 mg/kg, two of ten animals died at 2000 mg/kg, and ten of ten animals died at 3200 mg/kg. Necrosis of the skin was observed at the application site of all treated animals. The dermal LD₅₀ was calculated to be 1908 mg/kg. Clinical signs associated with test material administration included abnormal gait, abnormal stance and tremors. In all instances tremors were transitory and occurred only on the day after dosing. At 1000 and 2000 mg/kg, abnormal gait and abnormal stance were noted for up to four days following dosing.

RECEIVED
8-10-94

TSCA 8(e) Submission
n-Propylethanolamine
March 1, 1994
Page 2

It is the opinion of Elf Atochem that the effects noted in this study do not necessarily support a conclusion of substantial health risk, but are being submitted in response to the EPA 8(e) reporting standards.

Elf Atochem has not previously filed any 8(e) notices or Premanufacture Notifications (PMNs) on the subject material.

A copy of the final report will be forwarded to the Agency when it is received.

Further questions regarding this submission may be directed to me at (610) 337-6892.

Sincerely,



C.H. Farr, PhD, DABT
Manager, Product Safety
and Toxicology

Enclosure